GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TC BioPharm (Holdings) PLC (OTCPK:TCBPY) » Definitions » EV-to-EBIT

TCBPY (TC BioPharm (Holdings)) EV-to-EBIT : -0.14 (As of May. 16, 2025)


View and export this data going back to 2022. Start your Free Trial

What is TC BioPharm (Holdings) EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, TC BioPharm (Holdings)'s Enterprise Value is $1.01 Mil. TC BioPharm (Holdings)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-6.99 Mil. Therefore, TC BioPharm (Holdings)'s EV-to-EBIT for today is -0.14.

The historical rank and industry rank for TC BioPharm (Holdings)'s EV-to-EBIT or its related term are showing as below:

TCBPY' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.55   Med: 0   Max: 0
Current: -0.14

TCBPY's EV-to-EBIT is ranked worse than
100% of 474 companies
in the Biotechnology industry
Industry Median: 6.81 vs TCBPY: -0.14

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. TC BioPharm (Holdings)'s Enterprise Value for the quarter that ended in Jun. 2024 was $4.92 Mil. TC BioPharm (Holdings)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was $-6.99 Mil. TC BioPharm (Holdings)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -142.18%.


TC BioPharm (Holdings) EV-to-EBIT Historical Data

The historical data trend for TC BioPharm (Holdings)'s EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TC BioPharm (Holdings) EV-to-EBIT Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - - 1.65 -0.20

TC BioPharm (Holdings) Quarterly Data
Dec19 Dec20 Sep21 Dec21 Jun22 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.93 -0.41 -0.20 -0.59 -0.68

Competitive Comparison of TC BioPharm (Holdings)'s EV-to-EBIT

For the Biotechnology subindustry, TC BioPharm (Holdings)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TC BioPharm (Holdings)'s EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TC BioPharm (Holdings)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TC BioPharm (Holdings)'s EV-to-EBIT falls into.


;
;

TC BioPharm (Holdings) EV-to-EBIT Calculation

TC BioPharm (Holdings)'s EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1.013/-6.989
=-0.14

TC BioPharm (Holdings)'s current Enterprise Value is $1.01 Mil.
TC BioPharm (Holdings)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TC BioPharm (Holdings)  (OTCPK:TCBPY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

TC BioPharm (Holdings)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-6.989/4.915528
=-142.18 %

TC BioPharm (Holdings)'s Enterprise Value for the quarter that ended in Jun. 2024 was $4.92 Mil.
TC BioPharm (Holdings)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TC BioPharm (Holdings) EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of TC BioPharm (Holdings)'s EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


TC BioPharm (Holdings) Business Description

Traded in Other Exchanges
N/A
Address
Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
Executives
Renaissance Capital Partners Ltd 10 percent owner 42 SHAD THAMES, LONDON X0 SE1 2YD
Diana Elizabeth Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Kenneth Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD
Mark Edward Randall 10 percent owner C/O RENAISSANCE CAPITAL PARTNERS LTD, 42 SHAD THAMES, LONDON X0 SE1 2YD